Brussels-based drug company UCB has announced that executive vice-president and chief financial officer Mr Luc Missorten will leave the company on 1 September 2007.
Mr Missorten joined UCB in February 2004 as general manager of UCB Pharma Spain and was appointed chief financial officer in November 2004.
UCB is a biopharmaceutical company researching, developing and commercialising pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. It owns 87.6% of Schwarz Pharma.
Press release 2/7/2007